AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

URGN · NASDAQ · Biotechnology

UroGen Pharma

Develops localized mitomycin therapies for low-grade urothelial cancers.

$43.62

After-hours close−0.01 (−0.02%)

At close$43.63(−4.11%)

Something off on this page? Send us feedback.

Profile

UroGen Pharma Ltd.URGNHealth Care

Commercializes JELMYTO and ZUSDURI, RTGel-based mitomycin products for selected low-grade urothelial cancers, primarily in the United States. The single-segment business depends on specialist adoption, distributor-based product sales, FDA-regulated indications, and follow-on RTGel programs.

Uses RTGel, a reverse-thermal hydrogel, to keep mitomycin in local contact with urothelial tumors. Marketed products include JELMYTO for low-grade upper tract urothelial cancer and ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

Operates as one reportable segment with product sales primarily in the United States through national specialty distributors. The model is small and focused, built around physician adoption in urology and moving procedure-heavy treatment settings toward localized drug therapy.

Execution depends on FDA-approved indications, reimbursement, specialty-distributor access, commercialization of JELMYTO and ZUSDURI, and follow-on RTGel programs. JELMYTO also carries a future generic-license path under the Teva settlement if a generic version receives FDA approval.

Company facts

CEOElizabeth (Liz) Barrett

ListedMay 4, 2017

ExchangeNASDAQ

HeadquartersPrinceton, NJ

CountryUnited States

Employees291

CIK0001668243

ISINIL0011407140

Key statistics

Market cap$2.13B

EPS (ttm)−$1.98

P/E (ttm)−22.03

ROE81.8%

P/B−16.60

P/S11.26

Dividend yield—

Beta1.18vs XLV 0.56

Year to date +92.1% · Average volume (30d) 876.9K

Analysts

Price target, next 12 months$50.00+14.6%Median of 16 analysts · vs the Aug 28 close

ConsensusBuy12 of 16 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $43.62

High$75.00+71.9%

Median$50.00+14.6%

Low$40.00−8.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 6, 2026	Guggenheim	Reiterate	Buy	$42	$58
Aug 6, 2026	H.C. Wainwright	Reiterate	Buy	$45	$75
Jul 21, 2026	Guggenheim	Reiterate	Buy		$42
Jul 16, 2026	Oppenheimer	Reiterate	Outperform	$31	$50
Jul 15, 2026	Goldman Sachs	Reiterate	Neutral	$16	$44

Earnings

EPS

Estimate$0.10

ReportedDue Nov 5, 2026

Revenue

Estimate$90.6M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.27	−$0.28	−5.7%	$63.5M	$72.5M	+14.0%	+16.31%
May 6, 2026Q1 FY26	−$0.56	−$0.47	+16.1%	$44.8M	$51.0M	+13.7%	+1.30%
Mar 2, 2026Q4 FY25	−$0.52	−$0.54	−4.2%	$39.9M	$37.8M	−5.2%	−1.05%
Nov 6, 2025Q3 FY25	−$0.72	−$0.69	+4.2%	$40.1M	$27.5M	−31.5%	−1.27%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$20.3M	$24.2M	$27.5M	$37.8M	$51.0M	$72.5M
Gross profit	$17.9M	$20.7M	$24.2M	$34.5M	$46.8M	$65.9M
Operating income	−$36.9M	−$41.4M	−$27.4M	−$19.1M	−$20.3M	$111.0K
Net income	−$43.8M	−$49.9M	−$33.3M	−$26.4M	−$23.6M	−$14.4M
Diluted EPS	−$0.92	−$1.05	−$0.69	−$0.54	−$0.47	−$0.28
Gross margin	88.5%	85.3%	88.1%	91.3%	91.9%	90.9%
Operating margin	-182.3%	-171.2%	-99.7%	-50.5%	-39.8%	0.2%

Fiscal years (4-quarter sums)FY21 $48.0M · FY22 $64.4M · FY23 $82.7M · FY24 $90.4M · FY25 $109.8M

Revenue by product · Q2 FY26

Jelmyto$22.0M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $108.0M · Total debt $196.1M · Total assets $252.6M · Shareholders' equity −$132.4M

Dividends

No dividends on record.

Ownership

Institutions 95.32%46.44M sharesInsiders 0.26%128.7K sharesOther 4.42%2.15M shares

Shares outstanding 48.72M · Float 43.34M · 89.0% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
RTW Investments, LP	4.54M	9.33%	13F	May 15, 2026
Phillip Gross	3.74M	8.87%	13G	Nov 12, 2024
BlackRock, Inc.	2.85M	5.84%	13F	May 13, 2026
The Toronto-Dominion Bank	2.62M	5.40%	13G	May 15, 2026
Morgan Stanley	2.56M	5.25%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 20, 2026	Mark Schoenberg	officer: Chief Medical Officer	−60,677	$47.05
Jul 9, 2026	Mark Schoenberg	officer: Chief Medical Officer	−10,000	$40.00
Jun 22, 2026	Mark Schoenberg	officer: Chief Medical Officer	−10,000	$35.01
Jun 8, 2026	Mark Schoenberg	officer: Chief Medical Officer	−5,222	$27.30
May 8, 2026	Mark Schoenberg	officer: Chief Medical Officer	−10,000	$30.00